Alexion will acquire Portola, a California-based commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders.
Portola’s commercialized medicine, Andexxa®, is the first and only approved Factor Xa inhibitor reversal agent
“The acquisition of Portola represents an important next step in our strategy to diversify. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion.